Cargando…
Diabetes medications and risk of HCC
Type 2 diabetes mellitus is a recognized risk factor for HCC in patients with liver disease, independent from the etiology of their liver disease. Hence, prevention and treatment of type 2 diabetes mellitus and its underlying cause, insulin resistance, should be considered a treatment target for pat...
Autores principales: | Plaz Torres, Maria Corina, Jaffe, Ariel, Perry, Rachel, Marabotto, Elisa, Strazzabosco, Mario, Giannini, Edoardo G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790535/ https://www.ncbi.nlm.nih.gov/pubmed/35239194 http://dx.doi.org/10.1002/hep.32439 |
Ejemplares similares
-
Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?
por: Plaz Torres, Maria Corina, et al.
Publicado: (2020) -
Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis
por: Kayali, Stefano, et al.
Publicado: (2022) -
Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease?
por: Plaz Torres, Maria Corina, et al.
Publicado: (2020) -
Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered
por: Plaz Torres, Maria Corina, et al.
Publicado: (2019) -
Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting
por: Plaz Torres, Maria Corina, et al.
Publicado: (2021)